Death cap poisoning: what it is and how it manifests itself

The death cap (Amanita phalloides) is the leading cause of fatal mushroom poisoning worldwide: amatoxins (α-, β-, and γ-amanitin) account for more than 90-95% of mushroom-related fatalities. The toxins are heat-stable and are not destroyed by cooking, drying, or pickling. The key mechanism is the inhibition of RNA polymerase II in hepatocytes and other proliferating cells, leading to transcription arrest, apoptosis, and acute liver failure. [1]

The clinical course is typically three-phase: a latent period of 6-24 hours without symptoms → severe gastrointestinal symptoms (repeated vomiting, watery diarrhea, abdominal pain) → short-term "apparent improvement" → full-blown liver failure with jaundice, coagulopathy, and encephalopathy. It is this "lucid interval" that often lulls vigilance and delays seeking help. [2]

The current management strategy is based on early decontamination with activated charcoal (including multiple doses), specific therapy with silibinin (IV form of Legalon® SIL, where available) and N-acetylcysteine (NAC) as a safe adjuvant; indications for liver transplantation are assessed according to generally accepted criteria for acute liver failure (King's College, Clichy, etc.). For severe cases, albumin dialysis (MARS/ECAD) is considered as a "bridge" to regeneration or transplantation. [3]

Diagnosis is confirmed by a combination of clinical symptoms, laboratory changes, and detection of amatoxins in urine using LC-MS/MS (detection window up to ~4 days). Hemodialysis and traditional hemoperfusion do not effectively remove amatoxins; the emphasis is on supporting vital functions, interrupting enterohepatic circulation of the toxin, and early referral to a specialized center. [4]

Epidemiology

According to toxicological registries and surveys, amatoxin poisoning accounts for a small proportion of all mushroom intoxication cases, but accounts for the lion's share of fatalities (≥90%). In Europe, A. phalloides is considered the "most dangerous," with regular outbreaks during harvest seasons; its prevalence is increasing due to confusion with similar edible species and the mushroom's migration to new regions. [5]

Poison control center publications report mortality rates in the range of 10-40% in hospitalized patients, depending on the delay in presentation, availability of silibinin, and transplant options. In some series from North America and Europe, with organized care, mortality rates are significantly lower but remain clinically significant. [6]

Poisonings have been reported in people of all ages, including children; children are more likely to develop dehydration and hypoglycemia during the gastrointestinal phase. Seasonality coincides with peak fruiting and warm, rainy weather; the risk of outbreaks increases with the popularization of "silent hunting." [7]

International reviews emphasize that despite its rarity in the population, the burden on the healthcare system is high due to the need for intensive care units, liver resuscitation, and sometimes transplants. This justifies the creation of regional routes for suspected amatoxin poisoning. [8]

Reasons

The main cause is the accidental consumption of death caps and related deadly poisonous species (e.g., Amanita virosa, A. bisporigera ), sometimes as part of "mixed" dishes where the poisonous mushroom is mixed with edible ones. Mistakes occur when they resemble champignons, russula, greenfinch, or young "dead caps" without the characteristic pattern. [9]

Amatoxins are cyclic octopeptides that are stable to heat and acid; cooking does not destroy them. The toxin is rapidly absorbed in the small intestine and partially undergoes enterohepatic circulation, which explains the benefits of multiple doses of activated charcoal. [10]

Misidentification by sellers/gatherers, including migrants accustomed to similar edible species in their native regions, can also pose a risk. Misidentification is exacerbated by consumption in the dark, drying, and the use of "homemade clues" not based on mycology. [11]

In a number of outbreaks, mixed intoxication (e.g., the addition of irritating gastrointestinal species) has been described, which can cause early gastrointestinal symptoms and mask the amatoxin profile. This requires high vigilance even with "short" latency. [12]

Risk factors

The clinical risk of severe outcome is increased by: delayed presentation (>24 hours), late initiation of decontamination and antidote therapy, childhood (rapid dehydration), pregnancy, and concomitant liver/kidney disease. Older age is associated with worse outcomes in acute liver failure. [13]

Household factors: eating "untested" mushrooms, foraging in new locations without an experienced guide, and combining different species in a single dish. Lack of access to a toxicology panel and specialized medications (intravenous silibinin) is a significant systemic factor. [14]

Biological and pharmacokinetic factors: high enteral absorption of amatoxins and their enterohepatic recirculation maintain exposure; concomitant diarrhea after "waves" can fluctuate concentrations. Patients with antioxidant system deficiencies are expected to have poorer tolerability. [15]

Clinical and organizational: delay in transportation to a center with the possibility of ECAD/MARS and transplantation, lack of reusable activated carbon, failure to recognize the “lucid interval”. [16]

Pathogenesis

Amatoxins directly inhibit RNA polymerase II, blocking mRNA synthesis, which leads to the cessation of protein synthesis, apoptosis, and necrosis of cells with high metabolic activity—primarily hepatocytes. This triggers a cytokine cascade, coagulopathy, mitochondrial dysfunction, and a systemic inflammatory response. [17]

After absorption, toxins undergo enterohepatic circulation: excreted in bile and reabsorbed in the intestine. Therefore, multiple doses of activated charcoal (MDAC) reduce re-absorption and are associated with better clinical outcomes, according to a 2024 meta-analysis. [18]

Kidney damage is possible both secondary (hepatorenal syndrome) and due to nephrotoxicity (especially in severe cases), including tubular damage; in this case, amatoxins disappear from the blood quickly, and are detected in the urine for up to 4 days, which is important for diagnosis. [19]

In severe cases, acute liver failure (ALF) with encephalopathy and multiorgan dysfunction develops; in some patients, the only salvation is liver transplantation or albumin dialysis bridge (MARS/ECAD). [20]

Symptoms

In the “classic” case, there is a latent period of 6-24 hours (fluctuations are possible), then a stormy gastrointestinal phase: repeated vomiting, “watery” diarrhea, cramping pains, increasing weakness and thirst; in children, rapid signs of dehydration (dry mucous membranes, infrequent urination, dizziness). [21]

After 12-36 hours, a "lucid interval" occurs—a false improvement with a subsidence of nausea and diarrhea. It is at this point that patients often discontinue observation, even though severe changes in the liver are already developing. This window cannot be considered safe. [22]

By 48-96 hours, the liver phase appears: weakness, jaundice, dark urine, light-colored stools, bleeding (gums, petechiae), sometimes hypoglycemia, drowsiness, and signs of encephalopathy (disorientation, tremors, "liver" odor) increase. Pain in the right hypochondrium is possible. [23]

In severe cases, renal failure, lactic acidosis, progressive coagulopathy, and hemodynamic instability occur. Without specialized care, the risk of death is high even in previously healthy individuals. [24]

Forms and stages

Three clinical stages are distinguished: latent (up to 24 hours), gastrointestinal (usually 24 hours), and hepatic/multi-organ (from 2-3 days). Variations include shortened latency (with mixed dishes containing irritating toxins) and prolonged latency with a lower dose. Table 1 summarizes the stages. [25]

Severity is assessed based on laboratory (ALT/AST, bilirubin, INR/INR, ammonia), clinical (degree of encephalopathy), and trends. A number of centers integrate ALF prognostic scales to decide on transfer to a transplant center. [26]

Renal involvement is considered a separate subtype of severe disease (hepatorenal syndrome and/or tubular dysfunction). In late presentation, a "mixed" scenario with simultaneous diarrhea, jaundice, and oliguria is possible. [27]

Skin manifestations are not typical for amatoxins (unlike some other fungal toxins), however, in cases of severe coagulopathy, petechiae, ecchymosis, and bleeding wounds may appear. [28]

Complications and consequences

The main threat is acute liver failure with coagulopathy and encephalopathy, the leading cause of death. Kidney failure (AKI/ARF) and electrolyte disturbances are often associated with massive diarrhea and vomiting. [29]

In the gastrointestinal phase, severe dehydration, metabolic acidosis, and hypoglycemia occur; in children, seizures may occur due to hypoglycemia and hyponatremia. The risk of bleeding increases as the INR increases. [30]

In later stages, multiple organ failure, sepsis (less commonly), and the need for mechanical ventilation, dialysis, and vasopressors are possible. Even if they survive, some patients require long-term rehabilitation, dietary therapy, and monitoring for the cognitive consequences of hepatic encephalopathy. [31]

After transplantation, prognosis is determined by general factors of ALF transplantation; early transfer to the center and bridging technologies (ECAD/MARS) improve the chances of a favorable outcome. [32]

Diagnostics

Basic panel: complete blood count (hemoconcentration, leukocytes, platelets), electrolytes, creatinine/urea, ALT/AST, bilirubin, albumin, INR/INR, ammonia, blood gases, glucose. Serial measurements are more important than single ones: trends help predict deterioration. [33]

Toxicological confirmation: LC-MS/MS detects α/β/γ-amanitin in urine for up to ~4 days after ingestion (the window is shorter in serum). Urine collection is recommended at initial exposure, prior to massive infusion therapy. This is important for surveillance and legally binding confirmation. [34]

Instrumental assessment: abdominal ultrasound (to rule out other pathologies, portal blood flow, bile ducts); in case of deterioration, CT scan to assess complications. Early communication with the transplant center and toxicologist is necessary. [35]

Differentiation must be made with viral hepatitis, drug-induced liver injury (including paracetamol), ischemic hepatitis, and other fungal syndromes. For any diarrhea that begins 6-24 hours after mushroom ingestion, until proven otherwise, consider amatoxins. [36]

Differential diagnosis

Foodborne toxicoinfections: similar early diarrhea/vomiting, but there is no “clear period” with subsequent development of liver failure; laboratory data show no significant increase in INR/bilirubin. [37]

Gyromitrin syndrome (lines): early gastrointestinal storm, then neurological “second wave” (headache, seizures) due to GABA deficiency; typically responds to pyridoxine; liver failure does not predominate. [38]

Muscarinic syndrome (talkers/innocibe): early (minutes-hours) SLUDGE profile (salivation, tears, sweating, bronchospasm, bradycardia), without delayed jaundice and coagulopathy. [39]

Other causes of ALF: viral hepatitis, paracetamol, ischemia, autoimmune hepatitis, Wilson's disease, etc. General ALF algorithms and prognostic scales (King's College, Clichy, MELD guidelines) are used to make decisions about transplantation. [40]

Treatment

1) Immediate measures and support. Resuscitation assessment of ABC, correction of hypovolemia and electrolytes, glucose monitoring (hypoglycemia prevention), antiemetics. Hospitalization (if possible, transfer to a center with experience in ALF management). Early initiation of N-acetylcysteine (NAC) as a safe adjuvant (IV with standard regimens as for ALF) - overall data show benefit and good tolerability. [41]

2) Decontamination and interruption of recirculation. If presentation is early, activated charcoal (single dose of 1 g/kg; if presentation is late, multiple doses (MDAC) to interrupt enterohepatic circulation). A 2024 systematic review showed an association between activated charcoal and a better outcome. Gastric lavage and syrup of ipecac are not recommended. [42]

3) Specific therapy: silibinin. Intravenous silibinin (Legalon® SIL; where available) is the drug with the best profile justification: it blocks the uptake of amatoxins by hepatocytes (OATP transporters) and improves survival when administered within 48 hours of mushroom ingestion. Typical regimens are: loading ~5 mg/kg, then ~20 mg/kg/day continuously until INR/enzymes are stabilized (exact dosages according to local protocol). There are no data on the benefit of adding high-dose benzylpenicillin on top of silibinin; penicillin has been used historically, but no convincing benefit has been found. [43]

4) Other measures. Ornithine aspartate, S-adenosylmethionine, and “hepatoprotectors” have no proven efficacy against amatoxins. Routine hemodialysis does not remove amatoxins; in ALF, albumin dialysis (MARS/ECAD) is applicable as a “bridge” to regeneration/transplantation. Early assessment of transplantability and contact with a transplant center according to the criteria for non-paracetamol ALF are indicated (see Table 6). [44]

5) Support in ALF. Monitoring of neurological status (encephalopathy), ammonia control, prevention of intracranial hypertension, vitamin K for coagulopathy, antibiotic prophylaxis as indicated, management of complications (hypoglycemia, acidosis, renal failure), early transfer to the intensive care unit/liver center. [45]

Table 1. Clinical phases of amatoxin poisoning

Phase	Time from reception	Key symptoms	Comments
Latent	6-24 hours	No complaints or mild discomfort	High alertness with a known technique
gastrointestinal phase	6-36 h	Vomiting, watery diarrhea, cramping pain	Risk of dehydration, electrolyte imbalances
"Lucid interval	12-36 h	Paradoxical improvement	We must not stop observing
Liver	48-96 hours+	Jaundice, ↑INR, encephalopathy, AKI	MARS/transplant decision [46]

Table 2. "Red flags" - immediate hospitalization

Sign	Why is it important?
Diarrhea/vomiting 6-24 hours after mushrooms	Amatoxin scenario
"Light interval" after a stormy gastrointestinal syndrome	Often precedes the liver phase
Jaundice, dark urine, ↑INR	ALF Deployment
Confusion, drowsiness	Liver encephalopathy
Oliguria/creatinine increase	Renal involvement [47]

Table 3. Diagnostics: what and when

Study	When	What does it give?
General/biochemical analysis, INR, ammonia	On admission and dynamics every 6-12 hours	Severity/Trend Assessment
LC-MS/MS of amatoxins in urine	Preferably in the first 72-96 hours	Confirmation of exposure
Ultrasound/CT scan of the abdominal cavity	According to the readings	Elimination of alternatives/complications
Contacting the ALF/Transplant Center	Early	MARS/LT Planning [48]

Table 4. Therapy: What really helps (and the level of evidence)

Method	The essence	Comments/Evidence
Activated carbon (including MDAC)	Interrupts enterohepatic circulation	Association with better outcomes (systematic review 2024)
N-acetylcysteine	Antioxidant/ALF modulator	Safe, likely useful as an adjuvant
Silibinin (IV)	OATP uptake block, cytoprotection	More effective when administered within ≤48 hours; regulations vary by region
MARS/ECAD	Albumin dialysis	"Bridge" to regeneration/transplantation
Benzylpenicillin (high doses)	Historical application	No additional benefit has been shown with silibinin [49]

Table 5. What does not work/is limited

Approach	Comment
Gastric lavage, emetics	Not recommended routinely, benefit risk < risk
Hemodialysis/hemoperfusion to remove toxin	Amatoxins are not effectively removed
"Hepatoprotectors" without evidence	No clinical efficacy in trials
Delayed hospitalization "until improvement"	Dangerous because of the "light" gap [50]

Table 6. Estimation for transplantation with non-paracetamol ALF (summary)

Model	Criteria (simplified)	Notes
King's College	INR >6.5 or ≥3 signs: age <10/>40; etiology "non-A non-B/drug"; duration of jaundice → encephalopathy >7 days; INR >3.5; bilirubin >300 μmol/L	Classical stratification, widely used
Clichy	Encephalopathy III-IV + factor V <20% (up to 30 years) or <30% (over 30)	Requires measurement of factor V
Additional models	MELD landmarks, dynamic models	Used as a supplement, not instead of clinical [51]

Table 7. Silibinin (IV): practical details

Parameter	Intelligence
When to start	As soon as possible, optimally ≤48 hours after administration
Doses (approximate)	Load ~5 mg/kg → then ~20 mg/kg/day continuously (according to local protocol)
Duration	Until clinical and laboratory parameters (INR/enzymes) stabilize
Note	Legalon® SIL is not available in all countries; in the US - under IND

Prevention

Individual. Never eat wild mushrooms unless the species has been confirmed by an experienced mycologist; do not rely on "folk tests" (a silver spoon, onion/milk, etc. do not work). Do not make "composite" dishes, do not mix unfamiliar species, and do not rely on external similarities to champinon. If any symptoms occur after eating mushrooms, seek medical attention immediately, even if you feel better the next day. [52]

Public health. Regional health services should support seasonal educational campaigns, routes for suspected amatoxins, access to activated charcoal (MDAC), NAC, silibinin, and ECAD/MARS technologies. For emergency room physicians, early triage algorithms (time from admission, onset of diarrhea within 6-24 hours, early urine collection for amatoxins) and communication protocols with ALF/transplant centers. [53]

Forecast

The prognosis is highly dependent on the time to initiation of therapy: early MDAC + NAC + silibinin (where available) and intensive correction of fluid and electrolyte imbalances reduce the risk of progression to ALF. With timely management, some patients recover without transplantation. [54]

In cases of late presentation, severe coagulopathy/encephalopathy, and renal involvement, the risk of mortality increases significantly. In such cases, the decision on MARS/ECAD and transplantation should be made early, taking into account the dynamics of INR, bilirubin, factor V, and the degree of encephalopathy. [55]

FAQ

• Is it true that the toxin can be detected in the blood?

In serum, the detection window is short; in urine, amatoxins are detectable for up to ~4 days using LC-MS/MS, which is the best laboratory confirmation method. [56]

• Should I flush my stomach or induce vomiting?

No. It is not routinely recommended due to questionable benefits and risks. Activated charcoal is preferred, and in late cases, multiple doses (MDAC) are recommended. [57]

• Which is more effective: silibinin or penicillin?

Historically, high-dose benzylpenicillin has been used, but no convincing advantages over supportive care have been demonstrated. Current reviews highlight intravenous silibinin as the preferred specific agent (when available), especially when onset is ≤48 hours. NAC is a safe adjuvant. [58]

• Does hemodialysis remove amatoxins?

Conventional dialysis - no. In severe cases, albumin dialysis (MARS/ECAD) is used for support and a "bridge" to regeneration or transplantation. [59]

• What are the criteria for transplantation in amatoxin ALF?

General models for non-paracetamol ALF are used (e.g. King's College and Clichy): INR, bilirubin, factor V and degree of encephalopathy are taken into account; the decision is always individualised by a liver centre consultation. [60]